Cordyceps Sunshine Biotech Holdings (RAJAF) Common Equity (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Common Equity history runs 6 years deep, the most recent figure standing at -$534551.0 for Q4 2025.

• In Q4 2025, Common Equity fell 42.34% year-over-year to -$534551.0; the TTM figure through Dec 2025 stood at -$534551.0 (down 42.34% YoY), while the FY2025 annual figure was -$534551.0, down 42.34% from the prior year.
• Common Equity was -$534551.0 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, down from -$375543.0 in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$151796.0 in Q4 2023 to a low of -$951334.0 in Q4 2022.
• Historically, Common Equity has averaged -$457807.4 across 5 years, with a median of -$375543.0 in 2024.
• The sharpest annual moves came in 2021 and 2023: Common Equity plunged 2052.77% in 2021, then surged 84.04% in 2023.
• A 5-year view of Common Equity shows it stood at -$275813.0 in 2021, then tumbled by 244.92% to -$951334.0 in 2022, then soared by 84.04% to -$151796.0 in 2023, then slumped by 147.4% to -$375543.0 in 2024, then tumbled by 42.34% to -$534551.0 in 2025.
• The last three Common Equity figures came in at -$534551.0 (Q4 2025), -$375543.0 (Q4 2024), and -$151796.0 (Q4 2023), per Business Quant data.